Janssen Pharmaceutical, belonging to the American multinational Johnson & Johnson, foresees having the vaccine against covid-19, in whose phase III trials Spain participates, in the second semester of 2021 at a price of less than 10 dollars.
This was revealed this Thursday by the vice president of the Executive Committee of Johnson & Johnson, Joaquín Duato, in a conference at the Sectorial Meeting of the Health Sector, organized by IESE Business School, with the collaboration of the consulting firm McKinsey & Company.
The study, approved yesterday in Spain by the Spanish Agency for Medicines and Health Products, plans to guarantee the vaccine “at some point in the first or second half of 2021,” he declared.
Also read: AstraZeneca vaccine, with immune response in older adults
The first clinical results of Pfizer and Moderna, with a 95% efficiency, sare figures that suppose “good omens” for the rest of pharmaceutical companies focused on the same protein.
As reported by the Johnson & Johnson executive, the pharmaceutical company has worked in the supply chain to be able to offer one billion vaccines in 2021 through a collaborative network.
“During the next six months there will be good news, we will be able to see how these effective vaccines will be available to the public”, emphasized Duato, who has taken the opportunity to emphasize that the vaccine in which his team works will also guarantee “the standards of quality and safety “announced by other companies in the sector.
The speaker applauded the collaboration between partners in the pharmaceutical industry to find a vaccine: “It is not a competitive situation, it is a social issue and a global crisis in which we will need several vaccines, not just one, because we must vaccinate millions of people “.
To guarantee the vaccination of the population, Johnson & Johnson works together with the governments in access and distribution plans, as is the case of COVAX, a project to which they will allocate 500 million doses of its production for the lower-income countries.
From the multinational they assure that the price will not focus on profit: We will seek to guarantee access to the vaccine in all territories, the price will not be more than 10 dollars per vaccine. “